Technology Listings


Transgenic MRI Reporter to Monitor Stem Cells In Vivo

Application

Non-toxic MRI contrast that can be monitored in vivo during cell replacement therapy.

Key Benefits
  • Based on a magnetosome associated prokaryotic gene, MagA, leading to lower toxicity than nanoparticle systems.
  • MagA can be used to monitor stem cell graft non-invasively.
Technical Summary

Cell replacement therapy and regenerative medicine has been investigated for treating incurable diseases including diabetes, autoimmune diseases, and neurodegenerative diseases. In these treatments, it is difficult to monitor the fate of grafted cells in a non-invasive manner over the lifetime of the cell graft. Magnetic resonance imaging (MRI) and other imaging methods are capable of imaging deep tissues with high spatial and temporal resolution. Current methods for providing MR contrast to grafted cells have incorporated nanoparticles; however dilution and toxicity remain a concern with these systems. Emory inventors have developed a potential MRI reporter using a genetic reporter system that allows for long-term monitoring of grafted cells. Expression of this magnetosome associated prokaryotic gene, MagA, accumulates iron, leading to T2 MRI contrast that has shown lower toxicity than currently used nanoparticle systems. Furthermore, the growth rate, live-dead count, and caspase-3 expression of cells suggest lower toxicity of MagA on mouse embryonic stem cells (mESCs) compared to current MR contrast.

Publication: Cho IK, et al., (2014). Theranostics. 4 (10): 972-989.

Patent Information
Tech ID: 13210
Published: 1/19/2016
Category
Research Tools
Diagnostics

Contact
Hyeon (Sean) Kim
Licensing Associate
Emory University
hkim70@emory.edu

Inventor(s)
Anthony Wing Sang Chan
Hui Mao
In Ki Cho

Keywords